APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026

20 December 2025149 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF) include Changchun GeneScience Pharmaceutical, Evive Biotech, Teva, CSPC Baike Biopharma, Shanghai Sunway Biotech, Sandoz, Amoytop Biotech, Qilu Pharmaceutical and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Granulocyte-Colony Stimulating Factor (G-CSF) Market by Company

Changchun GeneScience Pharmaceutical

Evive Biotech

Teva

CSPC Baike Biopharma

Shanghai Sunway Biotech

Sandoz

Amoytop Biotech

Qilu Pharmaceutical

Mylan

Lunan Pharmaceutical

Kexing Biopharm

Jiangsu Hengrui Pharmaceuticals

Pfizer

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

SL Pharm

Amgen

Tanvex BioPharma

Kashiv BioSciences

Italfarmaco SpA

Coherus BioSciences

Chugai Pharmaceutical

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Long-acting G-CSF

Short-acting G-CSF

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Neutropenia

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Granulocyte-Colony Stimulating Factor (G-CSF) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Granulocyte-Colony Stimulating Factor (G-CSF) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units) of Manufacturers (2021-2026) Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue of Manufacturers (2021-2026) Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application Table 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Changchun GeneScience Pharmaceutical Company Information Table 19. Changchun GeneScience Pharmaceutical Business Overview Table 20. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 22. Changchun GeneScience Pharmaceutical Recent Developments Table 23. Evive Biotech Company Information Table 24. Evive Biotech Business Overview Table 25. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 27. Evive Biotech Recent Developments Table 28. Teva Company Information Table 29. Teva Business Overview Table 30. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 32. Teva Recent Developments Table 33. CSPC Baike Biopharma Company Information Table 34. CSPC Baike Biopharma Business Overview Table 35. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 37. CSPC Baike Biopharma Recent Developments Table 38. Shanghai Sunway Biotech Company Information Table 39. Shanghai Sunway Biotech Business Overview Table 40. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 42. Shanghai Sunway Biotech Recent Developments Table 43. Sandoz Company Information Table 44. Sandoz Business Overview Table 45. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 47. Sandoz Recent Developments Table 48. Amoytop Biotech Company Information Table 49. Amoytop Biotech Business Overview Table 50. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 52. Amoytop Biotech Recent Developments Table 53. Qilu Pharmaceutical Company Information Table 54. Qilu Pharmaceutical Business Overview Table 55. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 57. Qilu Pharmaceutical Recent Developments Table 58. Mylan Company Information Table 59. Mylan Business Overview Table 60. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 62. Mylan Recent Developments Table 63. Lunan Pharmaceutical Company Information Table 64. Lunan Pharmaceutical Business Overview Table 65. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 67. Lunan Pharmaceutical Recent Developments Table 68. Kexing Biopharm Company Information Table 69. Kexing Biopharm Business Overview Table 70. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 72. Kexing Biopharm Recent Developments Table 73. Jiangsu Hengrui Pharmaceuticals Company Information Table 74. Jiangsu Hengrui Pharmaceuticals Business Overview Table 75. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 77. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 82. Pfizer Recent Developments Table 83. North China Pharmaceutical Company Information Table 84. North China Pharmaceutical Business Overview Table 85. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 87. North China Pharmaceutical Recent Developments Table 88. Hangzhou Jiuyuan Gene Engineering Company Information Table 89. Hangzhou Jiuyuan Gene Engineering Business Overview Table 90. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 92. Hangzhou Jiuyuan Gene Engineering Recent Developments Table 93. Harbin Pharmaceutical Group Company Information Table 94. Harbin Pharmaceutical Group Business Overview Table 95. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 97. Harbin Pharmaceutical Group Recent Developments Table 98. SL Pharm Company Information Table 99. SL Pharm Business Overview Table 100. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 102. SL Pharm Recent Developments Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 107. Amgen Recent Developments Table 108. Tanvex BioPharma Company Information Table 109. Tanvex BioPharma Business Overview Table 110. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 112. Tanvex BioPharma Recent Developments Table 113. Kashiv BioSciences Company Information Table 114. Kashiv BioSciences Business Overview Table 115. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 117. Kashiv BioSciences Recent Developments Table 118. Italfarmaco SpA Company Information Table 119. Italfarmaco SpA Business Overview Table 120. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 122. Italfarmaco SpA Recent Developments Table 123. Coherus BioSciences Company Information Table 124. Coherus BioSciences Business Overview Table 125. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 127. Coherus BioSciences Recent Developments Table 128. Chugai Pharmaceutical Company Information Table 129. Chugai Pharmaceutical Business Overview Table 130. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 132. Chugai Pharmaceutical Recent Developments Table 133. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 134. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (k units) Table 135. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 136. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032) & (k units) Table 137. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027-2032) Table 138. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & (US$ Million) Table 139. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026) Table 140. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032) & (US$ Million) Table 141. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027-2032) Table 142. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 144. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 145. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 146. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 147. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 149. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 150. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 151. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 152. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 154. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 155. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 156. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 157. South America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 159. South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 160. South America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 161. South America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 162. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 164. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 165. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 167. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (k units) Table 168. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (k units) Table 169. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026) Table 170. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027-2032) Table 171. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 172. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 173. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026) Table 174. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027-2032) Table 175. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2026) & (US$/unit) Table 176. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2027-2032) & (US$/unit) Table 177. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (k units) Table 178. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (k units) Table 179. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026) Table 180. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027-2032) Table 181. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 182. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 183. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026) Table 184. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027-2032) Table 185. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2026) & (US$/unit) Table 186. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2027-2032) & (US$/unit) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 190. Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 191. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 192. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 193. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 194. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032) & (US$ Million) Figure 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (k units) Figure 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/unit) & (2021-2032) Figure 9. Long-acting G-CSF Product Image Figure 10. Short-acting G-CSF Product Image Figure 11. Neutropenia Product Image Figure 12. Other Product Image Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region in 2025 Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region in 2025 Figure 20. North America Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 21. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 22. North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 23. United States Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 27. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 28. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 29. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 40. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 42. China Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 51. South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 52. South America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 53. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 58. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 60. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032) Figure 66. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032) Figure 67. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/unit) by Type (2021-2032) Figure 68. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032) Figure 69. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032) Figure 70. Global Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/unit) by Application (2021-2032) Figure 71. Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 72. Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Long-acting G-CSF
  • Short-acting G-CSF
Applications
  • Neutropenia
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • Evive Biotech
  • Teva
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Sandoz
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Mylan
  • Lunan Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • SL Pharm
  • Amgen
  • Tanvex BioPharma
  • Kashiv BioSciences
  • Italfarmaco SpA
  • Coherus BioSciences
  • Chugai Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032)
  4. 2.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032)
  5. 2.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021-2032)
  6. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Long-acting G-CSF
  9. 2.3.3 Short-acting G-CSF
  10. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Neutropenia
  13. 2.4.3 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application
  8. 3.8 Global Manufacturers of Granulocyte-Colony Stimulating Factor (G-CSF), Established Date
  9. 3.9 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Changchun GeneScience Pharmaceutical
  2. 4.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 4.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 4.1.3 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 4.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 4.2 Evive Biotech
  8. 4.2.1 Evive Biotech Company Information
  9. 4.2.2 Evive Biotech Business Overview
  10. 4.2.3 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 4.2.5 Evive Biotech Recent Developments
  13. 4.3 Teva
  14. 4.3.1 Teva Company Information
  15. 4.3.2 Teva Business Overview
  16. 4.3.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 4.3.5 Teva Recent Developments
  19. 4.4 CSPC Baike Biopharma
  20. 4.4.1 CSPC Baike Biopharma Company Information
  21. 4.4.2 CSPC Baike Biopharma Business Overview
  22. 4.4.3 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 4.4.5 CSPC Baike Biopharma Recent Developments
  25. 4.5 Shanghai Sunway Biotech
  26. 4.5.1 Shanghai Sunway Biotech Company Information
  27. 4.5.2 Shanghai Sunway Biotech Business Overview
  28. 4.5.3 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 4.5.5 Shanghai Sunway Biotech Recent Developments
  31. 4.6 Sandoz
  32. 4.6.1 Sandoz Company Information
  33. 4.6.2 Sandoz Business Overview
  34. 4.6.3 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 4.6.5 Sandoz Recent Developments
  37. 4.7 Amoytop Biotech
  38. 4.7.1 Amoytop Biotech Company Information
  39. 4.7.2 Amoytop Biotech Business Overview
  40. 4.7.3 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 4.7.5 Amoytop Biotech Recent Developments
  43. 4.8 Qilu Pharmaceutical
  44. 4.8.1 Qilu Pharmaceutical Company Information
  45. 4.8.2 Qilu Pharmaceutical Business Overview
  46. 4.8.3 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 4.8.5 Qilu Pharmaceutical Recent Developments
  49. 4.9 Mylan
  50. 4.9.1 Mylan Company Information
  51. 4.9.2 Mylan Business Overview
  52. 4.9.3 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 4.9.5 Mylan Recent Developments
  55. 4.10 Lunan Pharmaceutical
  56. 4.10.1 Lunan Pharmaceutical Company Information
  57. 4.10.2 Lunan Pharmaceutical Business Overview
  58. 4.10.3 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 4.10.5 Lunan Pharmaceutical Recent Developments
  61. 4.11 Kexing Biopharm
  62. 4.11.1 Kexing Biopharm Company Information
  63. 4.11.2 Kexing Biopharm Business Overview
  64. 4.11.3 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 4.11.5 Kexing Biopharm Recent Developments
  67. 4.12 Jiangsu Hengrui Pharmaceuticals
  68. 4.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
  69. 4.12.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  70. 4.12.3 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 4.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  73. 4.13 Pfizer
  74. 4.13.1 Pfizer Company Information
  75. 4.13.2 Pfizer Business Overview
  76. 4.13.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 4.13.5 Pfizer Recent Developments
  79. 4.14 North China Pharmaceutical
  80. 4.14.1 North China Pharmaceutical Company Information
  81. 4.14.2 North China Pharmaceutical Business Overview
  82. 4.14.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 4.14.5 North China Pharmaceutical Recent Developments
  85. 4.15 Hangzhou Jiuyuan Gene Engineering
  86. 4.15.1 Hangzhou Jiuyuan Gene Engineering Company Information
  87. 4.15.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  88. 4.15.3 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 4.15.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  91. 4.16 Harbin Pharmaceutical Group
  92. 4.16.1 Harbin Pharmaceutical Group Company Information
  93. 4.16.2 Harbin Pharmaceutical Group Business Overview
  94. 4.16.3 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 4.16.5 Harbin Pharmaceutical Group Recent Developments
  97. 4.17 SL Pharm
  98. 4.17.1 SL Pharm Company Information
  99. 4.17.2 SL Pharm Business Overview
  100. 4.17.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  102. 4.17.5 SL Pharm Recent Developments
  103. 4.18 Amgen
  104. 4.18.1 Amgen Company Information
  105. 4.18.2 Amgen Business Overview
  106. 4.18.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  108. 4.18.5 Amgen Recent Developments
  109. 4.19 Tanvex BioPharma
  110. 4.19.1 Tanvex BioPharma Company Information
  111. 4.19.2 Tanvex BioPharma Business Overview
  112. 4.19.3 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  114. 4.19.5 Tanvex BioPharma Recent Developments
  115. 4.20 Kashiv BioSciences
  116. 4.20.1 Kashiv BioSciences Company Information
  117. 4.20.2 Kashiv BioSciences Business Overview
  118. 4.20.3 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  120. 4.20.5 Kashiv BioSciences Recent Developments
  121. 4.21 Italfarmaco SpA
  122. 4.21.1 Italfarmaco SpA Company Information
  123. 4.21.2 Italfarmaco SpA Business Overview
  124. 4.21.3 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  126. 4.21.5 Italfarmaco SpA Recent Developments
  127. 4.22 Coherus BioSciences
  128. 4.22.1 Coherus BioSciences Company Information
  129. 4.22.2 Coherus BioSciences Business Overview
  130. 4.22.3 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  132. 4.22.5 Coherus BioSciences Recent Developments
  133. 4.23 Chugai Pharmaceutical
  134. 4.23.1 Chugai Pharmaceutical Company Information
  135. 4.23.2 Chugai Pharmaceutical Business Overview
  136. 4.23.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  138. 4.23.5 Chugai Pharmaceutical Recent Developments
5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Scenario by Region
  1. 5.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2032
  3. 5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2026
  4. 5.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2027-2032
  5. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021-2032
  6. 5.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021-2026
  7. 5.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2027-2032
  8. 5.4 North America Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  9. 5.4.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  11. 5.4.3 North America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  16. 5.5.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  18. 5.5.3 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  41. 5.7.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  43. 5.7.3 South America Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  2. 6.1.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  5. 6.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  2. 7.1.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  5. 7.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 8.1.1 Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
  5. 8.2 Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  8. 8.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Customers
9 Global Granulocyte-Colony Stimulating Factor (G-CSF) Analyzing Market Dynamics
  1. 9.1 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 9.2 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 9.3 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 9.4 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst